About PAVmed Inc.
https://www.pavmed.comPAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay.
CEO
Lishan Aklog
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2026-01-02 | Reverse | 1:30 |
| 2023-12-07 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
AYRTON CAPITAL LLC
Shares:2.24M
Value:$20.62M
FIRST MANHATTAN CO. LLC.
Shares:714.1K
Value:$6.56M
VANGUARD GROUP INC
Shares:208.37K
Value:$1.91M
Summary
Showing Top 3 of 41
About PAVmed Inc.
https://www.pavmed.comPAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $5K ▼ | $4.79M ▲ | $-5.38M ▲ | -107.66K% ▲ | $-8.7 ▲ | $-5.98M ▲ |
| Q2-2025 | $6K ▼ | $4.68M ▼ | $-11.92M ▼ | -198.68K% ▼ | $-22.2 ▼ | $-12.3M ▼ |
| Q1-2025 | $8K ▼ | $5.38M ▲ | $18.97M ▲ | 237.1K% ▲ | $38.26 ▲ | $18.67M ▲ |
| Q4-2024 | $10K ▼ | $5.15M ▼ | $1.43M ▼ | 14.31K% ▲ | $3.61 ▼ | $1.22M ▼ |
| Q3-2024 | $996K | $11.19M | $64.4M | 6.47K% | $192.84 | $60.96M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $3.1M ▼ | $38.07M ▼ | $12.28M ▼ | $35.78M ▼ |
| Q2-2025 | $4M ▲ | $43.89M ▼ | $12.47M ▲ | $40.79M ▼ |
| Q1-2025 | $2.7M ▲ | $52.82M ▲ | $11.89M ▼ | $46.99M ▲ |
| Q4-2024 | $1.19M ▼ | $30.66M ▲ | $37.69M ▼ | $-2.5M ▲ |
| Q3-2024 | $1.25M | $30.55M | $39.94M | $-4.87M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-5.38M ▲ | $-896K ▲ | $-3K ▲ | $-2K ▼ | $-901K ▼ | $-899K ▲ |
| Q2-2025 | $-12.32M ▼ | $-1.18M ▲ | $-8K ▼ | $2.49M ▼ | $1.3M ▼ | $-1.19M ▲ |
| Q1-2025 | $18.62M ▲ | $-1.58M ▼ | $-6K ▼ | $3.1M ▲ | $1.51M ▲ | $-1.59M ▼ |
| Q4-2024 | $1.43M ▼ | $94K ▲ | $-4K ▲ | $330K ▲ | $420K ▲ | $90K ▲ |
| Q3-2024 | $60.71M | $-8.88M | $-16.14M | $284K | $-24.73M | $-8.89M |
Revenue by Products
| Product | Q3-2022 | Q4-2022 | Q1-2023 | Q2-2023 |
|---|---|---|---|---|
 Royalty | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Lishan Aklog
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2026-01-02 | Reverse | 1:30 |
| 2023-12-07 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
AYRTON CAPITAL LLC
Shares:2.24M
Value:$20.62M
FIRST MANHATTAN CO. LLC.
Shares:714.1K
Value:$6.56M
VANGUARD GROUP INC
Shares:208.37K
Value:$1.91M
Summary
Showing Top 3 of 41